annual cash & cash equivalents:
$596.07M+$260.07M(+77.40%)Summary
- As of today (September 5, 2025), HALO annual cash & cash equivalents is $596.07 million, with the most recent change of +$260.07 million (+77.40%) on December 31, 2024.
- During the last 3 years, HALO annual cash & cash equivalents has fallen by -$144.85 million (-19.55%).
- HALO annual cash & cash equivalents is now -19.55% below its all-time high of $740.92 million, reached on December 31, 2021.
Performance
HALO Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$548.18M-$199.75M(-26.71%)Summary
- As of today (September 5, 2025), HALO quarterly cash & cash equivalents is $548.18 million, with the most recent change of -$199.75 million (-26.71%) on June 30, 2025.
- Over the past year, HALO quarterly cash & cash equivalents has increased by +$19.15 million (+3.62%).
- HALO quarterly cash & cash equivalents is now -32.81% below its all-time high of $815.92 million, reached on September 30, 2021.
Performance
HALO quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
HALO Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +77.4% | +3.6% |
| 3 y3 years | -19.6% | +161.8% |
| 5 y5 years | +41.5% | +42.2% |
HALO Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -19.6% | +77.4% | -26.7% | +161.8% |
| 5 y | 5-year | -19.6% | +77.4% | -32.8% | +161.8% |
| alltime | all time | -19.6% | >+9999.0% | -32.8% | >+9999.0% |
HALO Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $548.18M(-26.7%) |
| Mar 2025 | - | $747.92M(+25.5%) |
| Dec 2024 | $596.07M(+77.4%) | $596.07M(-10.5%) |
| Sep 2024 | - | $666.31M(+25.9%) |
| Jun 2024 | - | $529.03M(+14.2%) |
| Mar 2024 | - | $463.45M(+37.9%) |
| Dec 2023 | $336.00M(-7.4%) | $336.00M(-30.5%) |
| Sep 2023 | - | $483.28M(+38.8%) |
| Jun 2023 | - | $348.27M(+26.4%) |
| Mar 2023 | - | $275.61M(-24.0%) |
| Dec 2022 | $362.79M(-51.0%) | $362.79M(+36.6%) |
| Sep 2022 | - | $265.58M(+26.9%) |
| Jun 2022 | - | $209.36M(-73.4%) |
| Mar 2022 | - | $786.14M(+6.1%) |
| Dec 2021 | $740.92M(+101.3%) | $740.92M(-9.2%) |
| Sep 2021 | - | $815.92M(+8.0%) |
| Jun 2021 | - | $755.31M(-1.2%) |
| Mar 2021 | - | $764.31M(+107.7%) |
| Dec 2020 | $368.01M(-12.6%) | $368.01M(+6.1%) |
| Sep 2020 | - | $346.71M(-10.1%) |
| Jun 2020 | - | $385.45M(+4.7%) |
| Mar 2020 | - | $368.18M(-12.6%) |
| Dec 2019 | $421.26M(+18.8%) | $421.26M(+77.0%) |
| Sep 2019 | - | $238.00M(-17.2%) |
| Jun 2019 | - | $287.46M(-12.5%) |
| Mar 2019 | - | $328.72M(-7.3%) |
| Dec 2018 | $354.53M(-24.4%) | $354.53M(-2.7%) |
| Sep 2018 | - | $364.37M(-8.7%) |
| Jun 2018 | - | $398.89M(-8.0%) |
| Mar 2018 | - | $433.69M(-7.6%) |
| Dec 2017 | $469.21M(+128.9%) | $469.21M(+48.1%) |
| Sep 2017 | - | $316.92M(+6.5%) |
| Jun 2017 | - | $297.53M(+66.2%) |
| Mar 2017 | - | $178.99M(-12.7%) |
| Dec 2016 | $204.98M(+89.2%) | $204.98M(-7.3%) |
| Sep 2016 | - | $221.05M(-3.9%) |
| Jun 2016 | - | $229.99M(-3.6%) |
| Mar 2016 | - | $238.64M(+120.3%) |
| Dec 2015 | $108.34M(-20.1%) | $108.34M(-12.4%) |
| Sep 2015 | - | $123.72M(-12.1%) |
| Jun 2015 | - | $140.72M(+9.5%) |
| Mar 2015 | - | $128.50M(-5.3%) |
| Dec 2014 | $135.62M | $135.62M(+0.9%) |
| Sep 2014 | - | $134.46M(-8.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2014 | - | $147.65M(-10.2%) |
| Mar 2014 | - | $164.49M(+130.0%) |
| Dec 2013 | $71.50M(-28.4%) | $71.50M(+9.5%) |
| Sep 2013 | - | $65.31M(-14.1%) |
| Jun 2013 | - | $76.01M(-13.1%) |
| Mar 2013 | - | $87.43M(-12.5%) |
| Dec 2012 | $99.90M(+89.1%) | $99.90M(+14.0%) |
| Sep 2012 | - | $87.61M(-14.1%) |
| Jun 2012 | - | $102.04M(-12.5%) |
| Mar 2012 | - | $116.61M(+120.7%) |
| Dec 2011 | $52.83M(-36.6%) | $52.83M(-20.4%) |
| Sep 2011 | - | $66.33M(-16.2%) |
| Jun 2011 | - | $79.12M(+7.2%) |
| Mar 2011 | - | $73.83M(-11.3%) |
| Dec 2010 | $83.26M(+30.7%) | $83.26M(-7.3%) |
| Sep 2010 | - | $89.84M(+117.5%) |
| Jun 2010 | - | $41.31M(-46.8%) |
| Sep 2009 | - | $77.64M(-13.0%) |
| Jun 2009 | - | $89.24M(+43.8%) |
| Mar 2009 | - | $62.07M(-2.6%) |
| Dec 2008 | $63.72M(-34.8%) | $63.72M(-12.1%) |
| Sep 2008 | - | $72.49M(-12.0%) |
| Jun 2008 | - | $82.41M(-11.0%) |
| Mar 2008 | - | $92.56M(-5.2%) |
| Dec 2007 | $97.68M(+121.0%) | $97.68M(-7.1%) |
| Sep 2007 | - | $105.11M(+4.5%) |
| Jun 2007 | - | $100.60M(+41.7%) |
| Mar 2007 | - | $70.97M(+60.6%) |
| Dec 2006 | $44.19M(+131.0%) | $44.19M(+174.5%) |
| Sep 2006 | - | $16.10M(+6.6%) |
| Jun 2006 | - | $15.10M(-14.1%) |
| Mar 2006 | - | $17.57M(-8.2%) |
| Dec 2005 | $19.13M(>+9900.0%) | $19.13M(+188.3%) |
| Sep 2005 | - | $6.64M(-34.0%) |
| Jun 2005 | - | $10.06M(-23.4%) |
| Mar 2005 | - | $13.13M(+277.3%) |
| Sep 2004 | - | $3.48M(-41.4%) |
| Jun 2004 | - | $5.94M(>+9900.0%) |
| Dec 2003 | $47.50K(-51.1%) | $47.50K(-24.1%) |
| Sep 2003 | - | $62.60K(-9.7%) |
| Jun 2003 | - | $69.30K(-28.7%) |
| Dec 2002 | $97.20K(+272.4%) | $97.20K(+620.0%) |
| Mar 2002 | - | $13.50K |
| Dec 2001 | $26.10K | - |
FAQ
- What is Halozyme Therapeutics, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Halozyme Therapeutics, Inc.?
- What is Halozyme Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
- What is Halozyme Therapeutics, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Halozyme Therapeutics, Inc.?
- What is Halozyme Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
What is Halozyme Therapeutics, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of HALO is $596.07M
What is the all time high annual cash & cash equivalents for Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. all-time high annual cash & cash equivalents is $740.92M
What is Halozyme Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, HALO annual cash & cash equivalents has changed by +$260.07M (+77.40%)
What is Halozyme Therapeutics, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of HALO is $548.18M
What is the all time high quarterly cash & cash equivalents for Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. all-time high quarterly cash & cash equivalents is $815.92M
What is Halozyme Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, HALO quarterly cash & cash equivalents has changed by +$19.15M (+3.62%)